[go: up one dir, main page]

WO2010089259A2 - Composition à libération prolongée contenant de la quétiapine - Google Patents

Composition à libération prolongée contenant de la quétiapine Download PDF

Info

Publication number
WO2010089259A2
WO2010089259A2 PCT/EP2010/051098 EP2010051098W WO2010089259A2 WO 2010089259 A2 WO2010089259 A2 WO 2010089259A2 EP 2010051098 W EP2010051098 W EP 2010051098W WO 2010089259 A2 WO2010089259 A2 WO 2010089259A2
Authority
WO
WIPO (PCT)
Prior art keywords
quetiapine
weight
optionally
particles
coating
Prior art date
Application number
PCT/EP2010/051098
Other languages
English (en)
Other versions
WO2010089259A3 (fr
Inventor
Juergen Heim
Sandra Weigel
Original Assignee
Woerwag R&D Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woerwag R&D Gmbh filed Critical Woerwag R&D Gmbh
Publication of WO2010089259A2 publication Critical patent/WO2010089259A2/fr
Publication of WO2010089259A3 publication Critical patent/WO2010089259A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention is directed to a sustained release pharmaceutical composition containing quetiapine, a pharmaceutically acceptable salt or a derivative thereof, which allows a once-a-day administration of said sustained release pharmaceutical composition to a patient in need thereof.
  • the present invention is further directed to the use of this composition for the treatment of schizophrenia and acute manic episodes associated with bipolar I disorder, and to a process for preparing the pharmaceutical composition.
  • the concentrations of the active compound in the blood are subject to high fluctuations when the drug formulation is administered repeatedly, as is customary in therapies.
  • the maximum concentrations of the active compound in the blood are usually reached within 4 hours. They then decrease considerably until the next administration occurs.
  • a multiple administration of tablet formulations having rapid release of the active compound results in high fluctuations of the concentration of the active compound in the blood.
  • a drug formulation having sustained or prolonged release offers a number of fundamental advantages, such as less frequent administration, which improves patient compliance. Additionally, advantages may be achieved in the case of certain diseases where even longer- lasting active compound levels than with an immediate or rapid release dosage form are important. Altogether, a drug formulation having sustained or delayed release offers greater possibilities to adjust the level of active compound to match the specific disease.
  • Quetiapin is an example for an active pharmaceutical ingredient that shows the above mentioned behaviour.
  • Said agent and its salts have been employed as pharmaceutically active agents in the treatment of schizophrenia and bipolar mania. Due to the high degree of bioavailability and rapid metabolism of quetiapine, the agent typically has to be administered twice a day.
  • Previously described formulations of quetiapine have certain properties that are not ideal under all circumstances. For example, previously disclosed formulations do not provide a constant or substantially constant level of quetiapine for 24 hours at steady-state. These previous formulations provide quetiapine blood or plasma concentrations that vary with time, i. e., at certain time points between administrations there are higher concentrations of quetiapine than at other times.
  • WO 2005/041935 describes quetiapine matrix formulations comprising wax
  • WO 2007/000778 describes a composition comprising two pH independent swellable polymers which are polyalkylene oxide and a hydrophilic polymer.
  • Improved control of pharmacokinetic properties may be achieved with alternative formulations, such as described in WO 2005/023228 or WO 03/039519.
  • Control of quetiapine plasma levels may be useful during treatment. For example, when a patient is present with an acute psychosis, it may be desirable to introduce an immediate large dosage of quetiapine, followed by a maintained sustained plasma level of quetiapine.
  • a sustained release pharmaceutical composition containing at least one form o f 2-(2- (4dibenzo[b,fJ[l,4]thiazepine-l l-yl-l-piperazinyl)ethoxy)ethanol (quetiapine), wherein the form of quetiapine is selected from the group consisting of quetiapine, a pharmaceutically acceptable salt of quetiapine, or a derivative or a pharmaceutically acceptable salt thereof, characterized in that it contains one or more populations of a form of quetiapine containing particles, such that following oral delivery to a subject, an in vivo peak plasma concentration of said form of quetiapine from about two to about eight hours after administration, and an in vivo release pattern is provided such that the blood plasma concentration of said form of quetiapine is as follows based on the overall content of said form of quetiapine: at 1 hour after delivery, 5 % to
  • the above release pattern is ideal for the once-a-day-administration of quetiapine to a patient in need thereof.
  • the present composition contains one or more populations of a form of quetiapine containing particles, or, in other words, is a multiparticulate composition.
  • a multiparticulate composition is defined as a composition, wherein the active ingredient is contained in several distinct units which allow an in vivo release not from one single entity only (such as a conventional compressed tablet), but a release from a multitude of entities once the composition enters the gastrointestinal tract of a patient.
  • quetiapine refers to quetiapine base, a pharmaceutically acceptable salt of quetiapine base, a derivative of quetiapine or a pharmaceutically acceptable salt of a derivative of quetiapine and combinations thereof.
  • quetiapine is quetiapine hemifumarate.
  • Other salts of quetiapine include oxalate, succinate, benzoate and formate salts.
  • the present compositions of quetiapine contain multiple particles.
  • the term "particle” is employed herein to in particular refer to pellets, beads, spheroids, granules, micro tablets, or mini tablets. Pellets, beads, spheroids or granules can be prepared according to any method known to persons skilled in the manufacture of pharmaceutical compositions.
  • the preferable particle size varies between 0.3 mm and 2.0 mm, in case of particles compressed into tablets between 0.1 mm and 0.6 mm.
  • pharmaceutically acceptable excipients are also involved in the particle forming process (and thus may be an integral part of the particles), which promote the formation of said particles of appropriate shape and surface.
  • excipients may be fillers, lubricants, glidants, antiadhesives, disintegrants or drug release controlling additives/agents, buffers, surfactants, surface-active substances, surface- active additives, pelletization promoting additives, or spheronization promoting substances.
  • Micro tablets, or mini tablets can be prepared according to any method known to persons skilled in the manufacture of pharmaceutical compositions.
  • the preferable micro/mini tablet size varies between 0.1 mm and 4.0 mm.
  • the one or more populations of a form of quetiapine containing particles preferably are provided in a formulation selected from the group consisting of matrix formulations, diffusion controlled membrane coated, encapsulated formulations and combinations thereof.
  • the particles are formulated as matrices, i.e. as a matrix dosage form comprising particles consisting of a pharmaceutical effective amount of a form of quetiapine, a sustained release (matrix forming) agent, optionally other excipients and optionally coatings.
  • sustained release matrix material or suitable combination of sustained release matrix materials may be used. Such materials are known to those skilled in the art.
  • the quetiapine comprising particles are forming a noneroding matrix formulation.
  • a noneroding matrix formulation preferably is a pharmaceutical composition, wherein the particles are comprising, a) a pharmaceutical effective amount of 20 % to 80 % by weight of a form of quetiapine, b) a sustained release matrix forming agent of 20 % to 70 % by weight, including lipophilic matrix materials like a water-insoluble and non-swellable material that slows the diffusion of the active agent, preferably waxes like beeswax or paraffines, hydrophilic matrix materials like a polymeric material that swells upon contact with water, and inert matrix materials,
  • the present invention comprises matrix formulations wherein the particles themselves are containing the matrix materials (and thus are forming the matrix), or, as an alternative, a formulation wherein particles which do not include a matrix material are embedded in a matrix material.
  • sustained release matrix forming agents include lipophilic matrix materials and inert matrix materials.
  • the typical matrix material if present, is a lipophilic matrix material.
  • a process for preparing a sustained release formulation of quetiapine as mentioned above comprises:
  • the polymer preferably has a viscosity of at least 15 mPas measured as a 2 % strength aqueous solution at 20 0 C.
  • the particles are formulated as erodible matrices.
  • a dosage form comprises particles consisting of a pharmaceutically effective amount of a form of quetiapine, an erodible matrix, optionally other excipients and optionally a coating.
  • the formulation may employ a sustained release coating and/or a sustained release matrix material, either or both of which dissolve in water over time, thus losing their structural integrity.
  • a sustained release coating and/or a sustained release matrix material dissolves after human ingestion over a controlled period of time.
  • the particles are comprising
  • an erodible/biodegradable matrix preferably 10 % to 70 % by weight, which optionally dissolves in water over time, thus losing its structural integrity, or is water insoluble,
  • a process for preparing the above mentioned formulation comprises the steps of:
  • the lubricant or lubricating material forms a film around the particles (granules) and helps the material flow, compress and eject from the tableting machine.
  • the lubricant or lubricating material may be present in levels up to 5 % by weight of the final composition.
  • particles contained in the composition of the invention may be particles with a rate rolling coating or membrane, for example a formulation comprising particles having a and an outer coating, the core comprising at least one form of quetiapine, a pharmaceutically acceptable carrier and optionally one or more excipients, and a rate controlling coating.
  • a rate rolling coating or membrane for example a formulation comprising particles having a and an outer coating, the core comprising at least one form of quetiapine, a pharmaceutically acceptable carrier and optionally one or more excipients, and a rate controlling coating.
  • the formulation contains particles comprising a core and an outer coating, the core comprising
  • particles differing in the thickness and/or material of the rate controlling layer are mixed before being combined in larger units.
  • the release profile can be tailored as desired.
  • the coating is preferably designed so that when the formulation enters the gastrointestinal tract, the particles absorb liquid, thus forming channels that interconnect the core with the outer surface of the coating.
  • the outer coating might include at least one plasticizer.
  • the amount of plasticizer or a mixture of plasticizers is optionally and more preferably in a range of from about 0 % to about 50 % weight per weight of the water insoluble polymer in the film coat.
  • a stiffening agent such as cetyl alcohol could optionally be used.
  • the outer coating may also optionally contain at least one of a wetting agent, suspending agent, surfactant, and dispersing agent, or a combination thereof, in addition to the plasticizer.
  • the content of the wetting agent, surfactant, dispersing agent and suspending agent may optionally be in an amount of from about 0 % to about 30 % of the weight of the film coat of the formulation.
  • the coating for this embodiment preferably comprises ethyl cellulose, cetyl alcohol, microcrystalline cellulose or calcium pectinate (CaP).
  • an enteric coating may be applied to these coated cores.
  • Each particle of the sustained release formulation comprising of 10 % (w/w) to 90 % (w/w) of one form of quetiapine, 10 % (w/w) to 90 % (w/w) of one more carriers, and optionally one or more pharmaceutically acceptable excipients; the said particles being coated with a coat comprising 1 % to 18 % by weight of each particle.
  • a process for preparing a sustained release formulation of quetiapine as mentioned above comprises:
  • the particles are in form of an osmotic-controlled formulation.
  • Said dosage forms, based on osmotic pressure can be achieved by preparing a core, containing a form of quetiapine dispersed in a combination of ingredients able to generate an osmotic pressure, when contained by an osmotic membrane.
  • the release from such systems is obtained with a calibrated hole in the membrane surrounding the particle which regulates, together with the level of osmotic pressure generated by the intrinsic characteristics of the particle core, the rate of release.
  • the particles containing a form of quetiapine might also be formulated with osmotic ingredients and coated with semipermeable film forming polymers to achieve zero-order release.
  • the osmotic device of the invention comprises at least one passageway (pore, hole, or aperture) which communicates the exterior of the semipermeable wall with the core of the device.
  • the passageway can be formed according to any of the known methods of forming passageways in a semipermeable membrane. Such methods include, for example,
  • the passageway can pass through the semipermeable wall and one or more of any other lamina coated onto the semipermeable membrane or between the semipermeable membrane and the core.
  • the passageway(s) can be shaped as desired.
  • the passageway is laser drilled and is shaped as an oval, ellipse, slot, slit, cross or circle.
  • the osmotic-controlled formulation comprises
  • said osmotic membrane consisting of semipermeable film forming polymers, preferably polymers that are high molecular weight derivatives of cellulose which are insoluble in water and might be selected from the group consisting of ethylcellulose with a degree of ethylation between 43 % and 50 %, cellulose acetate with 30 % to 45 % of acetyl value, polyvinylacetate, ammonium methacrylate copolymers, and mixtures thereof) to achieve zero-order release, and having a film thickness of the coating varying from 20 ⁇ m to 100 ⁇ m to achieve the desired extended release profile,
  • any other suitable process generate a passageway, where the passageway passes through the semipermeable wall and one or more of any other lamina coated onto the semipermeable membrane or between the semipermeable membrane and the core,
  • Osmotic ingredients can be any active principle ingredient with a solubility in aqueous media, in the range of pH from 1 to 7.5 and in an amount of not less than 0.1 %.
  • Any inorganic salt may be used which is highly dissociated in aqueous media in the range of pH from 1 to 7.5 and suitable to be included in pharmaceutical preparations for oral administration.
  • Semipermeable membranes are generally permeable to small solvent molecules, such as water, but comparatively impermeable to dissolved solutes. Even small ions are not readily exchanged across such membranes. Accordingly, semipermeable membranes, although able to prevent neutralizing ions from entering the core of an osmotically active dosage form, do not have the flexibility desired for modulating the rate of release of the beneficial agent from the device.
  • Semipermeable film forming polymers can be high molecular weight derivatives of cellulose which are insoluble in water as ethylcellulose with a degree of ethylation between 43 % and 50 %, cellulose acetate with 30 % to 45 % of acetyl value, polyvinylacetate, ammonium methacrylate copolymers.
  • Suitable plasticizers can be added in the range of 3 % to 40 %.
  • the film thickness may vary from 20 ⁇ m to 100 ⁇ m to achieve the desired extended release profile.
  • the size of the particles may vary between 0.1 mm to 7 mm of diameter and height. Depending on the composition of the core and on the type and thickness of the film different zero order kinetics can be achieved.
  • the particles are coated with a polymeric coating to form a delayed release formulation.
  • the delayed release oral dosage form is based on osmotic pressure and then a crown coating in the coating polymer formed in situ when the dose is ingested.
  • a process for preparing the above mentioned formulation comprises the steps
  • the invention also comprises a tablet or capsule containing an effective amount of particles with different release traits: thus, another embodiment of the present invention is a dosage form comprising a capsule or tablet containing immediate release particles as well as sustained release particles.
  • the formulation may comprise additional sustained release components as desired.
  • Said dosage form can in an embodiment be prepared as a pulsating/repeat release product, comprising a capsule having a plurality of particles, said particles comprising at least one form of quetiapine, at least one erodible polymer, optionally at least one lubricating.
  • a pulsating/repeat release product comprising a capsule having a plurality of particles, said particles comprising at least one form of quetiapine, at least one erodible polymer, optionally at least one lubricating.
  • To provide the pulsating/repeat release at least one of said plurality of particles is prepared from an erodible polymer having a first dissolution rate, and at least another of said plurality of particles is prepared from another or the same erodible polymer having a second dissolution rate, and said first dissolution rate is not equal to said second dissolution rate.
  • the different dissolution rates can be obtained either by using different materials or by using different thicknesses of the coating.
  • the pulsating/repeat release formulation comprising
  • a process for preparing the above mentioned formulation comprises the steps
  • step (c) optionally repeating of step (b) either with a different coating material or with a different thickness of the coating,
  • steps (c) and (d) repeating of steps (c) and (d) either with a different coating material or with a different thickness of the coating
  • excipients are the following:
  • Sustained release matrix forming agents include lipophilic matrix materials, hydrophilic matrix materials, inert matrix materials, and biodegradable matrix materials.
  • An inert matrix material provides a tortuous pathway and includes for example ethylcellulose.
  • the erodible matrix dosage form contemplates that the erodible polymer may be either water soluble or water insoluble.
  • a biodegradable matrix material includes polyesters of lactic acid and glycolic acid, polyorthoesters, polyanhydrides, and caprolactones.
  • Carriers might be selected from the group consisting of gum acacia, alginic acid, amino methacrylate copolymer, amonio methacrylate copolymer, calcium carbonate, calcium phosphate, calcium sulphate, carbomer copolymer, carbomer homopolymer, carbomer interpolymer, carboxymethylcellulose sodium, microcrystalline cellulose, copovidone, dextrates, dextrin, dextrose excipient, ethyl acrylate, ethylcellulose, fructose, gelatin, glucose, guar gum , 1 o w- substituted hydro xypropyl cellulose, hydro xypropylmethylcellulose (hypromellose), hypromellose acetate succinate, kaolin, keratin, lactitol, lactose, anhydrous lactose, lactose monohydrate, magnesium trisilicate, maltitol, maltodextrin, maltose,
  • Water insoluble polymers that are for example useful as inert matrix materials and for the described erodible matrix dosage form include, without limitation, amino methacrylate copolymer, cellulose acetate, cellulose acetate butyrate (cellaburate), cellulose acetate phthalate (cellacefate), cellulose acetate methyl carbamate, cellulose acetate valerate, cellulose trivalerate, cellulose trioctanoate, cellulose diacetate, cellulose triacetate, cellulose alkanylate, cellulose tripionate, cellulose diesters, cellulose disuccinate, cellulose acetaldehyde, dimethylcellulose acetate, cellulose dimethylaminoacetate, ethylcellulose (EC), methylcarbamate, polydiethylaminomethylstyrene, monoalkenytes, dialkenytes, trialkenytes, mono-, di-and tri-arolyates, polyvinylchloride, polyurethane, semipermeable s
  • a water insoluble but swellable polymer might be selected from the group consisting of a water insoluble polysaccharide, a water insoluble cross-linked polysaccharide, a water insoluble polysaccharide metal salt including calcium pectinate (CaP), a water insoluble cross-linked protein, a water insoluble cross-linked peptide, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, water insoluble cross-linked polyacrylic acid, water insoluble cross-linked cellulose derivatives , water insoluble cross-linked polyvinylpyrrolidone (crospovidone), microcrystalline cellulose, insoluble starch, microcrystalline starch and a combination thereof.
  • CaP calcium pectinate
  • a water insoluble cross-linked protein a water insoluble cross-linked peptide
  • water insoluble cross-linked gelatin water insoluble cross-linked hydrolyzed gelatin
  • water insoluble cross-linked collagen water insoluble cross-linked polyacryl
  • Water soluble polymers/hydrophilic matrix materials are selected from the group consisting of methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (HPC), hydroxyl- propylmethylcellulose (hydromellose, HPMC), hydroxypropylmethylcellulose- phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose acetate phthalate, carboxymethyl cellulose, carboxymethylcellulose sodium, methacrylic acid copolymer, ethylacrylate, polyacrylates, polyvinylpyrrolidon (PVP, Kollidone, povidone), a mixture of povidone and polyvinyl acetate, copovidone, polyvinyl alcohols (PVA), polyvinyl acetate, neutral methyl and/or ethyl ester compounds of polymethacrylic acid, propyleneglycol alginate, sodium alginate, gelatine, polysaccharides, maltodextrin, polyethylene glycol, starch, corn
  • Suitable binders and thickeners are, without limitation, selected from the group consisting of acacia, alginic acid, amino methacrylate copolymer, amonio methacrylate copolymer, calcium carbonate, calcium phosphate, calcium sulphate, carbomer copolymer, carbomer homopolymer, carbomer interpolymer, microcrystalline cellulose, methylcellulose, carboxymethylce llulo s e so dium, low-substituted hydroxypropyl cellulose, hydroxylpropylmethylcellulose (hypromellose), hypromellose acetate succinate, ethylcellulose, ethylacrylate, polyethylene oxide, dextrates, dextrin, dextrose excipient, fructose, gelatin, glucose, guar gum, kaolin, keratin, lactitol, lactose, anhydrous lactose, lactose monohydrate, magnesium trisilicate, malt
  • the mentioned diffusion coating includes at least one water insoluble hydrophobic polymer and at least one type of water insoluble but hydrophilic material or water soluble material embedded in the water insoluble polymer.
  • Suitable materials are, without limitation, selected from the group consisting of ethylcellulose, cellulose acetate or cellulose acetate butyrate, microcrystalline cellulose, cetyl alcohol, acrylates, calcium pectinate (CaP), and mixtures thereof.
  • Enteric coatings may contain, without any limitation, materials like or cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate succinate phthalate, hydroxylpropylmethylcellulose acetate succinate, a polymer sold under the trade mark Eudragit L, and mixtures thereof.
  • Suitable plasticizers are, for example, castor oil, acetylated fatty acid glycerides, citric acid derivatives (e. g. alkyl citrate and citrate esters such as tributyl citrate, triethyl citrate, and acetyl triethylcitrate, acetyltributyl citrate, acetyltriethyl citrate, tributyl citrate), acetylated monoglyceride , diacetylated mono glycerides, phthalic acid derivatives (e. g.
  • diaryl phthalates and mixed alkylaryl as represented by dimethyl phthalate, dipropyl phthalate, di-(2- ethylhexyl)-phthalate, di-isopropyl phthalate, diamyl phthalate and dicapryl phthalate, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, dialkyl phthalates, dicycloalkyl phthalates), alkyl and aryl phosphates such as tributyl phosphate, trioctyl phosphate, ricresyl phosphate and triphenyl phosphate, esters like diethyl sebacate, dibutyl sebacate, or triacetin, fatty acids and derivatives (e.
  • alkyl adipates such as dioctyl adipate, diethyl adipate and di-(2-methyoxy-ethyl)adipate
  • dialkyl tartrates such as diethyl tartrate and dibutyl succinate
  • plasticizers include camphor, N-ethyl- (o-and p-toluene)sulfonamide, chlorinated biphenyl, benzophenone, N-cyclohexyl-p-toluene sulfonamide, and substituted epoxides.
  • plasticizers suitable for osmotic devices include plasticizers that lower the temperature of the second-order phase transition of the wall of the elastic modulus thereof; and also increase the workability of the wall, its flexibility and its permeability to fluid.
  • Plasticizers operable for this purpose include both cyclic plasticizers and acyclic plasticizers.
  • Typical plasticizers are those selected from the group consisting of phthalates, phosphates, citrates, adipates, tartrates, sebacates, succinates, glycolates, glycerolates, benzoates, myristates, sulfonamides, and halogenated phenyls.
  • a non limiting example of a stiffening agent is cetyl alcohol.
  • wetting agents include, but are not limited to, poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyoxymethylene stearate, sodium lauryl sulfate, sorbitan fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, docusate sodium, and mixtures thereof.
  • suspending agents include, but are not limited to, alginic acid, bentonite, carbomer, carboxymethylcellulose, carboxymethylcellulose calcium, hydroxylethylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, colloidal silicon dioxide, dextrin, gelatin, guar gum, xanthan gum, kaolin, magnesium aluminum silicate, maltitol, medium chain triglycerides, methylcellulose, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyvinylpyrrolidone (PVP), propylene glycol alginate, sodium alginate, sorbitan fatty acid esters, tragacanth, and mixtures thereof.
  • alginic acid bentonite
  • carbomer carboxymethylcellulose
  • carboxymethylcellulose calcium hydroxylethylcellulose
  • hydroxypropyl cellulose microcrystalline cellulose
  • colloidal silicon dioxide dextrin
  • gelatin guar gum
  • xanthan gum kaolin
  • Suitable surfactants include, but are not limited to, anionic surfactants such as docusate sodium and sodium lauryl sulfate; cationic, such as cetrimide; nonionic, such as polyoxyethylene sorbitan fatty acid esters (polysorbates) and sorbitan fatty acid esters.
  • suitable dispersing agents include, but are not limited to, poloxamer, polyoxy ethylene sorbitan fatty acid esters (polysorbates) and sorbitan fatty acid esters.
  • Examples of usable lubricating materials include, without limitation, fats, emulsifiers, waxes, mineral oil, magnesium stearate, calcium stearate, talc, starches, silicon dioxide, polyethylene glycol, glycerine and propylene glycol, and mixtures thereof.
  • fats, or fatty materials useful herein include, without limitation, water insoluble, inert hydrocarbon fats or oils, or their derivatives and mixtures thereof.
  • Such fats or fatty materials include, for example and without limitation, cocoa butter, hydrogenated vegetable tallow, hydrogenated vegetable oils, and derivative mixtures thereof.
  • Glidants that may be applied during the processes described herein include e. g. colloidal silicon dioxide, magnesium stearate, talc, starch, and mixtures thereof.
  • the aforementioned emulsifiers include, without limitation, alkyl aryl sulfonates, alkyl sulfates, sulfonated amides and amines, sulfated and sulfonated esters and ethers, alkyl sulfonates, polyethoxylated esters, mono-and diglycerides, diactyl tartaric esters of monoglyderides, polyglycerol esters, sorbitan esters and ethoxylates, lactylated esters, propylene glycol esters, sucrose esters, and mixtures thereof.
  • Waxes include, for example, amorphous waxes, anionic emulsifying waxes, cationic emulsifying waxes, bleached waxes, caranda waxes, cetyl esters, microcrystalline waxes, paraffins, refined waxes, (white) beeswax, microcrystalline wax, carnauba wax, glyceride esters, hydrogenated vegetable (e. g.
  • hydrogenated castor oil as well as animal oils, stearyl alcohols and their derivatives, polyethylene glycols and their derivatives, glyceryl behenate, glyceryl palmito stearate, saturated polyglycolyzed glycerate, esters of fatty acids such as palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and mixtures thereof.
  • Suitable anti-adhesives are, without any limitation, kaolin, talk or silicon dioxide.
  • Disintegrants or drug release promoting agents are for example alginates, sodium carboxymethyl cellulose, crospovidon, starch, pre-gelatinized starch, sodium carboxymethyl starch, or e. g. ethylcellulose, carnauba wax, shellac.
  • Buffers may be citrate, phosphate, carbonate and hydro-carbonate salts.
  • Surface-active additives like polysorbate, sodium laurylsulfate and spheronization promoting substances as microcrystalline cellulose or a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose may also be used for the dosage forms.
  • Semipermeable materials can be any polymer permeable to water but impermeable to solutes. Examples include cellulose acetate; cellulose diacetate; cellulose triacetate; cellulose propionate; cellulose acetate butyrate; cellulose acetate; cellulose triacetylates such as cellulose trivalerate, cellulose trilaurate, cellulosetripalmitate, cellulose trisuccinate, cellulose triheptylate, cellulose tricaprylate, cellulose trioctanoate, and cellulosetripropionate; cellulose diesters such as cellulose dicapyrlate and cellulosedipentanate; and esters prepared from acyl anhydrides or acyl acids in an esterification reaction to yield esters containing different acyl groups attached to the same cellulose polymer such as cellulose acetate valerate, cellulose acetate succinate, cellulose propionate succinate, cellulose acetate octanoate, cellulose valerate palmitate, cellulose acetate palmitate
  • Osmotic agents i. e. materials that are capable of expanding in size upon imbibing water, include both, salt-containing and salt-free agents.
  • the osmotic agent may be an osmagent, an osmopolymer, or a mixture of the two.
  • Species that fall within the category of osmagent i.e., the non-volatile species that are soluble in water and create the osmotic gradient driving the osmotic inflow of water, vary widely.
  • examples include, without any limitation, magnesium sulfate, magnesium chloride, potassium sulfate, sodium chloride, sodium sulfate, lithium sulfate, sodium phosphate, potassium phosphate, d-mannitol, sorbitol, inositol, urea, magnesium succinate, tartaric acid, raffinose, and various monosaccharides, oligosaccharides and polysaccharides such as sucrose, glucose, lactose, fructose, and dextran, as well as mixtures of any of these various species.
  • Osmopolymers that fall within the category of osmopolymer are hydrophilic polymers that swell upon contact with water.
  • Osmopolymers may be of plant or animal origin, or synthetic, and examples of osmopolymers are known in the art.
  • Examples include: poly(hydroxy-alkyl methacrylates) with molecular weight of 30,000 to 5,000,000; poly(vinylpyrrolidone) with molecular weight of 3,000 to 20,000; anionic and cationic hydrogels, polyelectrolyte complexes, poly(vinyl alcohol) having low acetate residual, optionally cross linked with glyoxal, formaldehyde or glutaraldhyde and having a degree of polymerization of 200 to 30,000; a mixture of methyl cellulose, cross linked agar and carboxymethylcellulose, a mixture of hydro xypropylmethylcellulose and sodium carboxymethylcellulose; polymers of N-vinyllactams, polyoxyethylene-polyoxypropylene gels; polyoxybutylene-polyethylene block copolymer gels; carob gum; polyacrylic gels; polyester gels; polyurea gels; polyether gels; polyamide gels; polypeptide gels; polyamino acid gels; polycellul
  • Pore-formers used to contro l the pore size, are so luble polymers , such as carboxymethylcellulose, hydroxypropylmethylcelluloses, methylcelluloses, dextrins, maltodextrins, cyclo dextrins, dextrans, polyethylene glycols, polyvinylpyrrolidones, or other soluble compounds, such as, for example, salts (common salt, potassium chloride, ammonium chloride, etc.), sugars (glucose, sucrose, fructose, lactose, etc.), sugar alcohols (manitol, sorbitol, lactitol, etc.), urea, and mixtures thereof.
  • salts common salt, potassium chloride, ammonium chloride, etc.
  • sugars glucose, sucrose, fructose, lactose, etc.
  • sugar alcohols manitol, sorbitol, lactitol, etc.
  • urea and mixtures
  • Pore-formers for osmotic driven release formulations can be inorganic or organic.
  • Inorganic solid additives include alkali metal salts such as sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium benzoate, sodium acetate, sodium citrate, potassium nitrate and the like.
  • the alkaline earth metal salts such as calcium chloride, calcium nitrate, and the like.
  • the transition metal salts such as ferric chloride, ferrous sulfate, zinc sulfate, cupric chloride, and the like.
  • Water may also be used as the pore-former.
  • Organic pore-formers might be compounds such as saccharides.
  • the saccharides include the sugars sucrose, glucose, fructose, mannose, galactose, aldohexose, altrose, talose, lactose, monosaccharides, disaccharides, and water soluble polysaccharides.
  • sorbitol, manitol, organic aliphatic and aromatic ols including diols and polyols, as exemplified by polyhydric alcohols, poly (alkylene glycols), polyglycols, alkylene glycols, poly(a-co) alkylenediols, esters or alkylene glycols poly vinylalcohol, polyvinyl pyrrolidone, and water soluble polymeric materials.
  • Pores may also be formed in the wall by the volatilization of components in a polymer solution or by chemical reactions in a polymer solution which evolves gases prior to application or during application of the solution to the cores mass resulting in the creation of polymer foams serving as the porous wall of the invention.
  • the pore-formers are nontoxic, and on their removals, channels form that fill with fluid.
  • the channels become a transport path for fluid.
  • the non-toxic pore-forming agents are selected from the group consisting of inorganic and organic salts, carbohydrates, polyalkylene glycols, poly(a-co) alkylenediols, esters of alkylene glycols and glycols, that are used in a biological environment.
  • Additional polymers that can be used for the purpose of the invention include cellulose acetate acetoacetate, cellulose acetate chloroacetate, cellulose acetatefuroate, dimethoxyethyl cellulose acetate, cellulose acetate carboxymethoxy propionate, cellulose acetate benzoate, cellulose butyrate napthylate, methylcellulose acetate methy Icy ano ethyl cellulose, cellulose acetate methoxyacetate, cellulose acetate ethoxyacetate, cellulose acetate dimethylsulfamate, ethylcellulose, ethylcellulose dimethylsulfamate, cellulose acetate ptoluene sulfonate, cellulose acetate methylsulfonate, cellulose acetate dipropylsulfamate, cellulose acetate butylsulfonate, cellulose acetate laurate, cellulose stearate, cellulose acetate methyl
  • Admixtures of various polymers may also be used, for example glyceryl behenate and g lyc ero l o r suit ab ly c o mb in atio n s o f hi g h and low viscosity grades hydroxylpropylmethylcellulose, ethyl cellulose, glyceryl behenate and methyl cellulose.
  • the quetiapine or its salt or derivative is present in each component of the formulation in an amount of from about 0.1 mg to about 1 g, preferably in an amount of from about 0.1 mg to 500 mg, more preferably in an amount of from 0.5 to 50 mg, and more preferably in an amount of from 2.5 to 25 mg.
  • a formulation according to the present invention may be formulated into any suitable dosage form which facilitates the release of the antipsychotic agent.
  • the dosage form may, for example, be a capsule (e.g., a hard or soft gelatin capsule) which contains, therein, the above described particles.
  • the particles may exist therein in various forms, for example, in the form of mini-tablets, granules or pellets.
  • a capsule comprises a particle comprising an immediate release component and/or a particle comprising a delayed immediate release component and a particle comprising a sustained release component.
  • the particle comprising the sustained release component and the particle comprising the delayed immediate release component may, for example, be particles comprising quetiapine and one or more sustained release means.
  • the particle may be made out of a sustained release matrix material and/or coated with a sustained release coating.
  • the sustained release means may, for example, be a coating whose integrity is pH-dependent.
  • the particle comprising the immediate release component may, for example, be in the form of a particle which comprises quetiapine but not a sustained release means.
  • the capsule may, for example, comprise a mini-tablet comprising an immediate release component and/or a minitablet comprising a delayed immediate release component and a mini-tablet comprising a sustained release component.
  • the mini-tablets may be formed, for example, by compressing the above- described particles (e.g., a sustained release mini-tablet may be formed by compressing sustained release particles).
  • the particles may be, for example, in the form of multilayer tablets with one layer comprising an immediate release component or a delayed immediate release component and another layer comprising a sustained release component.
  • the sustained release formulations containing a form of quetiapine comprise amounts equivalent to 25 mg, 50 mg, 100 mg, 200 mg, 300 mg or 400 mg of quetiapine.
  • a method of effectively treating schizophrenia in humans comprising orally administering to a human patient on a once a day basis an oral sustained release dosage form containing at least one form of quetiapine.
  • a method for the treatment of acute manic episodes associated with bipolar I disorder in humans comprising orally administering to a human patient on a once a day basis an oral sustained release dosage form containing at least one form of quetiapine.
  • the dosage form described herein comprises quetiapine hemifumarate.
  • compositions comprising at least one form of quetiapine contain one or more additional active pharmaceutically ingredients.
  • the invention is directed to the use of the pharmaceutical composition of the invention for the manufacture of a medicament for the treatment of
  • the invention provides a general process for preparing the pharmaceutical compositions as disclosed above comprising the steps of
  • Quetiapine and its pharmaceutically acceptable salts may be prepared as described in published European Patents EP 0 240 228 or EP 0 282 236.
  • Example 1 Matrix tablet with coating:
  • Example 2 Matrix tablet with coating: Core: (95.17 % by weight of the final tablet)
  • Example 3 Eroding matrix tablet without coating:
  • Example 4 Eroding matrix tablet with coating:
  • Coating 1 (5.55 % by weight of the final tablet)
  • Coating 2 (6.52 % by weight of the final tablet)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique à libération prolongée contenant de la quétiapine, l'un de ses sels ou dérivés pharmaceutiquement acceptables, qui permet une simple administration quotidienne de ladite composition pharmaceutique à libération prolongée à un patient le nécessitant. La présente invention concerne en outre l'utilisation de cette composition pour le traitement de la schizophrénie et d'épisodes maniaques aigus associé au trouble bipolaire I, et un procédé de préparation de la composition pharmaceutique.
PCT/EP2010/051098 2009-02-04 2010-01-29 Composition à libération prolongée contenant de la quétiapine WO2010089259A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151996 2009-02-04
EP09151996.7 2009-02-04

Publications (2)

Publication Number Publication Date
WO2010089259A2 true WO2010089259A2 (fr) 2010-08-12
WO2010089259A3 WO2010089259A3 (fr) 2011-07-07

Family

ID=42060688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/051098 WO2010089259A2 (fr) 2009-02-04 2010-01-29 Composition à libération prolongée contenant de la quétiapine

Country Status (1)

Country Link
WO (1) WO2010089259A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438920A1 (fr) * 2010-10-08 2012-04-11 Sanovel Ilac Sanayi ve Ticaret A.S. Composition pharmaceutique à libération contrôlée de quetiapine
CN103315973A (zh) * 2013-05-24 2013-09-25 杭州和正医药有限公司 喹硫平的渗透泵型控释制剂
WO2014155387A1 (fr) * 2013-03-24 2014-10-02 Tushar Patel Formes galéniques à libération prolongée de sels de quétiapine
CN104688709A (zh) * 2015-03-24 2015-06-10 北京世桥生物制药有限公司 一种富马酸喹硫平组合物的缓释片剂及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240228A1 (fr) 1986-03-27 1987-10-07 Ici Americas Inc. Dérivés de thiazépine
EP0282236A1 (fr) 1987-03-10 1988-09-14 Imperial Chemical Industries Plc Procédé pour la préparation d'un dérive de thiazépine
WO1997045124A1 (fr) 1996-05-31 1997-12-04 Zeneca Limited Compositions pharmaceutiques
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
WO2003039519A2 (fr) 2001-11-06 2003-05-15 Osmotica Corp. Forme de dosage a liberation controlee duale
WO2005023228A1 (fr) 2003-09-05 2005-03-17 Shire Laboratories, Inc. Administration osmotique de composes therapeutiques par amelioration de la solubilite
WO2005041935A1 (fr) 2003-10-21 2005-05-12 Alpharma, Inc. Preparations pharmaceutiques contenant de la quetiapine
WO2007000778A2 (fr) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Compositions pharmaceutiques a liberation modifiee et leurs procedes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086079A2 (fr) * 2006-01-25 2007-08-02 Astron Research Limited Forme de dose a liberation soutenue de derives de phenothiazine contenant un canalisateur
WO2008090569A1 (fr) * 2007-01-25 2008-07-31 Panacea Biotec Ltd Composition pharmaceutique à libération modifiée et procédé de fabrication
US20080287418A1 (en) * 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
EP2153834A3 (fr) * 2008-08-07 2010-02-24 Farmaprojects, S.A. Compositions pharmaceutiques à libération prolongée comportant des sels de quétiapine
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240228A1 (fr) 1986-03-27 1987-10-07 Ici Americas Inc. Dérivés de thiazépine
EP0282236A1 (fr) 1987-03-10 1988-09-14 Imperial Chemical Industries Plc Procédé pour la préparation d'un dérive de thiazépine
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
WO1997045124A1 (fr) 1996-05-31 1997-12-04 Zeneca Limited Compositions pharmaceutiques
WO2003039519A2 (fr) 2001-11-06 2003-05-15 Osmotica Corp. Forme de dosage a liberation controlee duale
WO2005023228A1 (fr) 2003-09-05 2005-03-17 Shire Laboratories, Inc. Administration osmotique de composes therapeutiques par amelioration de la solubilite
WO2005041935A1 (fr) 2003-10-21 2005-05-12 Alpharma, Inc. Preparations pharmaceutiques contenant de la quetiapine
WO2007000778A2 (fr) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Compositions pharmaceutiques a liberation modifiee et leurs procedes

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438920A1 (fr) * 2010-10-08 2012-04-11 Sanovel Ilac Sanayi ve Ticaret A.S. Composition pharmaceutique à libération contrôlée de quetiapine
TR201008261A1 (tr) * 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
EP2438920B1 (fr) 2010-10-08 2016-09-28 Sanovel Ilac Sanayi Ve Ticaret A.S. Composition pharmaceutique à libération contrôlée de quetiapine
EP3090747A1 (fr) * 2010-10-08 2016-11-09 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations de quétiapine à libération contrôlée
EP3821894A1 (fr) * 2010-10-08 2021-05-19 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de quétiapine à libération contrôlée
WO2014155387A1 (fr) * 2013-03-24 2014-10-02 Tushar Patel Formes galéniques à libération prolongée de sels de quétiapine
CN103315973A (zh) * 2013-05-24 2013-09-25 杭州和正医药有限公司 喹硫平的渗透泵型控释制剂
CN104688709A (zh) * 2015-03-24 2015-06-10 北京世桥生物制药有限公司 一种富马酸喹硫平组合物的缓释片剂及其制备方法

Also Published As

Publication number Publication date
WO2010089259A3 (fr) 2011-07-07

Similar Documents

Publication Publication Date Title
US6569456B2 (en) Osmotic device containing diltiazem and an ACE inhibitor or diuretic
ES2489140T3 (es) Formas de dosificación oral para liberación modificada que comprenden tasocitinib
ES2523145T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
JP4500679B2 (ja) パリペリドンを制御送達する方法および投薬形態物
JP5285913B2 (ja) 経口投与できる固体の放出改変型医薬投与形
US8475813B2 (en) Methods of treatment using a gastric retained gabapentin dosage
KR20020031424A (ko) 1 일 1회 투여로 효과적인 레복세틴 치료를 제공하는 투여형태 및 방법
JP2008535877A (ja) 良性前立腺肥大症の治療用の組合せ
EP1246612A1 (fr) Dispositif osmotique contenant de la pseudoephedrine et un antagoniste de h1
JP2023505329A (ja) リオシグアトの放出調節医薬組成物
US6110499A (en) Phenytoin therapy
US8252331B2 (en) Osmotic device containing amantadine and an osmotic salt
JP5325421B2 (ja) アマンタジンおよび浸透塩を含有する浸透デバイス
WO2010089259A2 (fr) Composition à libération prolongée contenant de la quétiapine
US9889152B2 (en) Multiple PPI dosage form
US7147870B2 (en) Osmotic device containing pseudoephedrine and an H1 antagonist
AU2011205024B2 (en) Multiple PPI dosage form
WO2014167439A1 (fr) Compositions pharmaceutiques à libération modifiée de topiramate ou de sels de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10701546

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10701546

Country of ref document: EP

Kind code of ref document: A2